109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
寻常型银屑病患者在抑制 IL-17A 后的神经功能可逆性：静息态功能磁共振成像与神经认知分析
Authors Liu J , Fan H, Sun R, Pang Y, Li X, Ma Q , Xu C, Zhang D , Ma W
Received 16 July 2025
Accepted for publication 15 October 2025
Published 31 October 2025 Volume 2025:15 Pages 535—543
DOI https://doi.org/10.2147/PTT.S554255
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tina Bhutani
Jiayun Liu, Huiping Fan, Rui Sun, Yunyan Pang, Xiaojin Li, Qingsong Ma, Chen Xu, Dong Zhang, Weiyuan Ma
Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China
Correspondence: Dong Zhang, Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China, Tel +0086-536-3081272, Email dongdong.zd@163.com Weiyuan Ma, Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China, Tel +0086-536-3081272, Email fymaweiyuan@sdsmu.edu.cn
Purpose: Interleukin-17A (IL-17A) drives psoriasis and central nervous system neuroinflammation, but clinical research on whether IL-17A-targeted biotherapy modulates brain activity to improve neuropsychiatric outcomes in psoriasis is lacking. This study aims to investigate brain functional changes, cognitive impairment, and the effects of IL-17A monoclonal antibody therapy in psoriasis vulgaris.
Patients and methods: Regular secukinumab treatment. Meanwhile, 20 healthy controls (HCs) matched in age and gender were enrolled. The patients underwent functional magnetic resonance imaging (fMRI) before treatment and 48 weeks after treatment. The healthy controls also had fMRI scans. It assessed clinical data, cognition/neuropsych status (MoCA, SDS, SAS), disease severity/quality of Life (PASI/DLQI), and brain function via rs-fMRI (ALFF/ReHo).
Results: Compared to healthy controls, the psoriasis vulgaris patients showed increased ALFF in the frontal lobe, as well as increased frontal ReHo. The treatment group showed signal recovery in some brain regions. Patients before treatment had lower MoCA scores vs controls (P < 0.001)) and higher SAS/SDS scores (SAS, P < 0.0001; SDS, P < 0.05). Patients after treatment showed higher MoCA scores vs before treated (P < 0.05), similar to controls, with lower SAS scores (P < 0.0001) and reduced PASI/DLQI (P < 0.0001).
Conclusion: Psoriasis is associated with brain dysfunction and neuropsychiatric symptoms. IL-17A antibody therapy improves skin symptoms, restores brain function, and alleviates neuropsychiatric issues vs untreated patients, supporting multidimensional treatment.
Keywords: psoriasis vulgaris, rs-fMRI, brain function, cognitive impairment, IL-17A monoclonal antibody
Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China
Correspondence: Dong Zhang, Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China, Tel +0086-536-3081272, Email dongdong.zd@163.com Weiyuan Ma, Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, People’s Republic of China, Tel +0086-536-3081272, Email fymaweiyuan@sdsmu.edu.cn
Purpose: Interleukin-17A (IL-17A) drives psoriasis and central nervous system neuroinflammation, but clinical research on whether IL-17A-targeted biotherapy modulates brain activity to improve neuropsychiatric outcomes in psoriasis is lacking. This study aims to investigate brain functional changes, cognitive impairment, and the effects of IL-17A monoclonal antibody therapy in psoriasis vulgaris.
Patients and methods: Regular secukinumab treatment. Meanwhile, 20 healthy controls (HCs) matched in age and gender were enrolled. The patients underwent functional magnetic resonance imaging (fMRI) before treatment and 48 weeks after treatment. The healthy controls also had fMRI scans. It assessed clinical data, cognition/neuropsych status (MoCA, SDS, SAS), disease severity/quality of Life (PASI/DLQI), and brain function via rs-fMRI (ALFF/ReHo).
Results: Compared to healthy controls, the psoriasis vulgaris patients showed increased ALFF in the frontal lobe, as well as increased frontal ReHo. The treatment group showed signal recovery in some brain regions. Patients before treatment had lower MoCA scores vs controls (P < 0.001)) and higher SAS/SDS scores (SAS, P < 0.0001; SDS, P < 0.05). Patients after treatment showed higher MoCA scores vs before treated (P < 0.05), similar to controls, with lower SAS scores (P < 0.0001) and reduced PASI/DLQI (P < 0.0001).
Conclusion: Psoriasis is associated with brain dysfunction and neuropsychiatric symptoms. IL-17A antibody therapy improves skin symptoms, restores brain function, and alleviates neuropsychiatric issues vs untreated patients, supporting multidimensional treatment.
Keywords: psoriasis vulgaris, rs-fMRI, brain function, cognitive impairment, IL-17A monoclonal antibody